S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance

Inozyme Pharma - INZY Stock Forecast, Price & News

$3.04
+0.28 (+10.14%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.76
$3.18
50-Day Range
$1.71
$3.25
52-Week Range
$0.99
$6.25
Volume
837,730 shs
Average Volume
1.60 million shs
Market Capitalization
$122.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.75

Inozyme Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
483.9% Upside
$17.75 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.84) to ($1.87) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

583rd out of 983 stocks

Pharmaceutical Preparations Industry

280th out of 478 stocks


INZY stock logo

About Inozyme Pharma (NASDAQ:INZY) Stock

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

INZY Stock News Headlines

Why Earnings Season Could Be Great for Inozyme (INZY)
Could This Be The Biggest Stock Of 2023?
This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!pixel
Why Inozyme Pharma (INZY) Shares Are Trading Higher Today
Short Volatility Alert: Inozyme Pharma Inc
Needham Reaffirms Their Buy Rating on Inozyme Pharma (INZY)
Could This Be The Biggest Stock Of 2023?
This Little Known Company Has Been Growing It's Revenue By Over 100% Year Over Year!pixel
INZY Soars on Promising INZ-701 Data
INZY Inozyme Pharma, Inc.
See More Headlines
Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

INZY Company Calendar

Last Earnings
11/09/2021
Today
3/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INZY
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.75
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+483.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-56,620,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.62 per share

Miscellaneous

Free Float
36,468,000
Market Cap
$122.79 million
Optionable
Not Optionable
Beta
0.79

Key Executives

  • Mr. Axel Bolte M.B.A. (Age 50)
    M.Sc., Co-Founder, Pres, CEO & Director
    Comp: $889.66k
  • Mr. Henric Bjorn Bjarke (Age 55)
    Sr. VP & COO
    Comp: $597.68k
  • Dr. Demetrios Braddock M.D.
    Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer
  • Mr. Sanjay S. Subramanian M.B.A. (Age 45)
    M.S., CFO & Principal Accounting Officer
  • Dr. Soojin Kim Ph.D.
    Sr. VP & Chief Technical Operations Officer
  • Dr. Yves Sabbagh Ph.D.
    Chairman of Scientific Advisory Board, Sr. VP & Chief Scientific Officer
  • Mr. Stefan Riley
    Director of Investor Relations
  • Ms. Gayle Gironda
    Sr. VP & Chief People Officer
  • Dr. David Thompson M.A.
    M.S., Ph.D., Chief Devel. Officer
  • Mr. Stephen J. Di Palma M.B.A (Age 63)
    M.B.A., Consultant













INZY Stock - Frequently Asked Questions

Should I buy or sell Inozyme Pharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INZY shares.
View INZY analyst ratings
or view top-rated stocks.

What is Inozyme Pharma's stock price forecast for 2023?

4 Wall Street research analysts have issued 1 year target prices for Inozyme Pharma's stock. Their INZY share price forecasts range from $5.00 to $23.00. On average, they predict the company's stock price to reach $17.75 in the next twelve months. This suggests a possible upside of 483.9% from the stock's current price.
View analysts price targets for INZY
or view top-rated stocks among Wall Street analysts.

How have INZY shares performed in 2023?

Inozyme Pharma's stock was trading at $1.05 at the beginning of the year. Since then, INZY shares have increased by 189.5% and is now trading at $3.04.
View the best growth stocks for 2023 here
.

How were Inozyme Pharma's earnings last quarter?

Inozyme Pharma, Inc. (NASDAQ:INZY) issued its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.01.

What other stocks do shareholders of Inozyme Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inozyme Pharma investors own include Honeywell International (HON), Procter & Gamble (PG), Raytheon Technologies (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS), Home Depot (HD), Resideo Technologies (REZI), Thermo Fisher Scientific (TMO) and Abbott Laboratories (ABT).

When did Inozyme Pharma IPO?

(INZY) raised $75 million in an IPO on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Inozyme Pharma's stock symbol?

Inozyme Pharma trades on the NASDAQ under the ticker symbol "INZY."

Who are Inozyme Pharma's major shareholders?

Inozyme Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (6.04%), Sphera Funds Management LTD. (4.02%), Millennium Management LLC (0.74%), Renaissance Technologies LLC (0.64%), State of Wisconsin Investment Board (0.09%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Axel Bolte, Henric Bjorn Bjarke, Holdings A/S Novo, Longitude Capital Partners Iii and Robert Lorne Hopfner.
View institutional ownership trends
.

How do I buy shares of Inozyme Pharma?

Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Inozyme Pharma's stock price today?

One share of INZY stock can currently be purchased for approximately $3.04.

How much money does Inozyme Pharma make?

Inozyme Pharma (NASDAQ:INZY) has a market capitalization of $122.79 million. The company earns $-56,620,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis.

How can I contact Inozyme Pharma?

The official website for the company is www.inozyme.com. The company can be reached via phone at 857-330-4340 or via email at ir@inozyme.com.

This page (NASDAQ:INZY) was last updated on 3/22/2023 by MarketBeat.com Staff